Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02115295
Title Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

myelodysplastic syndrome

acute leukemia

chronic myeloid leukemia

Therapies

Cladribine + Cytarabine + Idarubicin

Midostaurin

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
M D Anderson Cancer Center Recruiting Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field